

RECEIVED

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number	Application Number
	30436.30USI2	09/609,915
	Applicant	
	Peter S. Linsley et al.	
	Filing Date	Group Art Unit
	July 3, 2000	1646

[illegible]

EXAMINER <i>J. Specto</i>	DATE CONSIDERED <i>u/9/04</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	
*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	

FORM 1449*

**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number

30436.30US12

Application Number

09/609,915

Applicant

Peter S. Linsley et al.

Filing Date

July 3, 2000

Group Art Unit

1646

U.S. PATENT DOCUMENTS



EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>[Signature]</i>	6,444,792 (Exhibit 223)	September 3, 2002	Gray et al.			January 8, 1999
	5,770,197 (Exhibit 227)	June 23, 1998	Peter S. Linsley et al.			January 22, 1993
	6,132,992 (Exhibit 228)	October 17, 2000	Jeffrey A. Ledbetter et al.			October 5, 1995
	6,090,914 (Exhibit 229)	July 18, 2000	Peter S. Linsley et al.			April 15, 1994
	5,773,253 (Exhibit 230)	June 30, 1998	Peter S. Linsley et al.			July 21, 1995
	5,977,318 (Exhibit 231)	November 2, 1999	Peter S. Linsley et al.			June 7, 1995
	5,885,579 (Exhibit 232)	March 23, 1999	Peter S. Linsley et al.			July 8, 1997
	5,993,800 (Exhibit 233)	November 30, 1999	Peter S. Linsley et al.			June 6, 1995
	5,916,560 (Exhibit 234)	June 29, 1999	Christian P. Larsen et al.			March 20, 1997
	5,968,510 (Exhibit 242)	October 19, 1999	Linsley et al.			October 4, 1996
	5,958,403 (Exhibit 254)	September 28, 1999	Strom et al.			July 11, 1994
<i>[Signature]</i>	5,637,481 (Exhibit 258)	June 10, 1997	Ledbetter et al.			September 13, 1993

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



FORM 1449*

**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number

30436.30USI2

Application Number

09/609885

Applicant

Peter S. Linsley et al.

Filing Date

July 3, 2000

Group Art Unit

1646

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AS ↓	WO 98/31820 (Exhibit 221)	July 23, 1998	PCT				
	WO 94/28912 (Exhibit 222)	December 22, 1994	PCT				
	WO 93/19767 (Exhibit 224)	October 14, 1993	PCT				
	WO 94/29436 (Exhibit 225)	December 22, 1994	PCT				
	WO 95/33823 (Exhibit 226)	December 14, 1995	PCT				
	EP 0 613 944 A2 (Exhibit 235)	September 7, 1994	EPO				
	WO 98/56417 (Exhibit 238)	December 17, 1998	PCT				
	WO 01/92337 (Exhibit 243)	December 6, 2001	PCT				
	WO 98/33513 (Exhibit 252)	August 6, 1998	PCT				
	WO 02/02638 (Exhibit 253)	January 10, 2002	PCT				
↓	EP 0 682 039 A1 (Exhibit 256)	November 15, 1995	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)



AS ↓		Peach et al., "Complementarity Determining Region 1 (CDR1)- and CDR3-analogous in CTLA-4 and CD28 Determine the Binding to B7-1," (1994) J. Exp. Med. 180:2049-2058. (Exhibit 236)
↓		Morton et al., "Differential Effects of CTLA-4 Substitutions on the Binding of Human CD80 (B7-1) and CD86 (B7-2)," (1996) J. Immunol. 156:1047-1054. (Exhibit 237)
↓		Sun, Hong et al., "Prevention of Chronic Rejection in Mouse Aortic Allografts by Combined Treatment with CTLA4-Ig and Anti-CD40 Ligand Monoclonal Antibody," Transplantation, 1997, 64:1838-56 (Exhibit 239)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION


 JUN 19 2003
 IPO
 PATENT & TRADE MARK OFFICE

09/609,915

Group Art Unit

1646

Souza, "Synergistic inhibition of established collagen induced arthritis (CIA) through dual inhibition of ICAM-1 and CD40L pathways," *Arthritis and Rheumatism*, 1999, page S60; abstract 64 (Exhibit 240)

Blazar, Bruce R. et al., "Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 Pathways Is A Highly Effective Means of Preventing Acute Lethal Graft-Versus-Host Disease Induced by Fully Major Histocompatibility Complex-Disparate Donor Grafts," *Blood*, 1995, 85:2607-18 (Exhibit 241)

Alegre et al., "Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors," *Dig. Dis. Sci.*, 1995, 40:58-64 (Exhibit 244)

Murakami et al., "Identification and characterization of an alternative cytotoxic T lymphocyte-associated protein 4 binding molecule on B cells," *Proc. Nat. Acad. Sci. USA*, 1996, 3:7838-7842 (Exhibit 245)

Peach et al., "Both extracellular immunoglobulin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28," *J. Biol. Chem.*, 1995, 270:21181-21187 (Exhibit 246)

Fargeas et al., "Identification of Residues in the V Domain of CD80 (B7-1) Implicated in Functional Interactions with CD28 and CTLA4," *J. Exp. Med.*, 1995, 182:667-675 (Exhibit 247)

Steurer et al., "Ex Vivo Coating of Islet Cell Allografts with Murin CTLA4/Fc Promotes Graft Tolerance," *J. Immunol.*, 1995, 155:1165-1174 (Exhibit 248)

Guo et al., "Mutational Analysis and an Alternatively Spliced Product of B7 Defines Its CD28/CTLA4-binding Site on Immunoglobulin C-like Domain," *J. Exp. Med.*, 1995, 181:1345-1355 (Exhibit 249)

Peach et al., "CTLA4Ig: A Novel Immunoglobulin Chimera with Immunosuppressive Properties," *Methods*, 1995, 8:116-123 (Exhibit 250)

Rattis et al., "Expression and function of B7-1 (CD80) and B7-2 (CD86) on human epidermal Langerhans cells," *Eur. J. Immunol.*, 1996, 26:449-453 (Exhibit 251)

Najafian, et al., "CTLA4-Ig: a novel immunosuppressive agent," *Exp. Opin. Invest. Drugs*, 2000, 9:2147-2157 (Exhibit 255)

Schwartz, R., "Costimulation of T Lymphocytes: The Role of CD28, CTLA-4, and B7/BB1 in Interleukin-2 Production and Immunotherapy," *Cell*, 1992, 71:1085-1088. (Exhibit 257)

DATE CONSIDERED

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

(Use several sheets if necessary)

30436.30US12

09/609,915

Applicants

Peter S. Linsley et al.

Filing Date

July 3, 2000

Group Art Unit

1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

* Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



FORM 1449*

INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

(Use several sheets if necessary)

Docket Number

30436.30US12

Application Number

09/609,915

Applicants

Peter S. Linsley et al.

Filing Date

July 3, 2000

Group Art Unit

1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

RECEIVED

NOV 28 2003

~~TECH CENTER 1600/2900~~

EXAMINER

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE